Page 154 - 80 guidelines for the treatment of malaria_opt
P. 154

nd
              Guidelines for the treatment of malaria – 2  edition edition
              Guidelines for the treatment of malaria – 2  nd
                         importance  CRITICAL  IMPORTANT  CRITICAL  IMPORTANT  IMPORTANT  IMPORTANT  IMPORTANT





                         Quality  MODERATE  MODERATE  VERY LOW
                                                        LOW     LOW      LOW      –
                              128 fewer per 1000   (from 111 fewer to 137   267 fewer per 1000   (from 242 fewer to 287   8 more per 1000 (from   117 more per 1000   (from 55 more to 217   13 fewer per 1000   (from 20 fewer to    1 more per 1000 (from


                       Absolute   fewer)  fewer)  9 fewer to    52 more)  more)  0 more)  6 fewer to    14 more)  –




                    effect  Relative risk   (95% CI)  RR 0.12   (0.06–0.24)  RR 0.35   (0.3–0.41)  RR 1.39   (0.55–3.47)  RR 3.17   (2.01–5.01)  RR 0.46   (0.21–1.01)  RR 1.08   (0.56–2.08)  –


                  summary of findings  no. of patients  AQ + SP   AL  67/459    8/460    (14.6%)  (1.7%)  398/971    144/978   (41%)  (14.7%)  8/390    10/360    (2.1%)  (2.8%)  22/404    73/423   (5.4%)  (17.3%)  19/775    8/761    (2.5%)  (1.1%)  18/1365   16/1319   (1.3%)  (1.2%)  –  –
              Is AL superior to AQ+SP for treating uncomplicated P. falciparum malaria in Africa?






                         considerations

                       Other    None   None    None     None    None     None     –


                       Imprecision  No serious   imprecision 8  No serious   imprecision 8  Very    serious 13  No serious   imprecision 14  Serious 17  Very serious 13  –



                       Indirectness  Serious 6,7  Serious 6,7  Very    serious 12  Very    serious 12  No serious   indirectness  No serious   indirectness  –



                       Inconsistency  No serious   inconsistency 5 EFFICACy: total failure (P. falciparum) day 28 PCR unadjusted – Africa (excluding Burkina Faso)  No serious   inconsistency 5  No serious   inconsistency 5  No serious   inconsistency 5  No serious   inconsistency 5  No serious   inconsistency 5



                       Limitations EFFICACy: total failure (P. falciparum) day 28 PCR adjusted – Africa (excluding Burkina Faso) 1  No serious   limitations 3,4  No serious   limitations 3,4 EFFICACy: total failure (P. falciparum) day 28 PCR adjusted – Burkina Faso 9  No serious   limitations 11 EFFICACy: total failure (P. falciparum) day 28 PCR unadjusted –

            GRADE Table A7.1.3   Quality assessment  Design  Randomized   trial 2  Randomized   trial 2  Randomized   trial 10  Randomized   trial 10 TRANSMISSION POTENTIAL: gametocyte carriage day 14 15  Randomized   trial  HARMS: serious adverse events (including deaths)  Randomized   trial  HARMS: early vomiting – not reported 19  –  –










   140                 No. of   studies  3  4  2        2       4        5        0
   149   150   151   152   153   154   155   156   157   158   159